CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Dextrose Monohydrate 50% Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current, To Be Discontinued. First FDA posting: 2022-01-13. Latest FDA row update: 2026-09-22.
FDA lists 4 package records, with companies: Amphastar Pharmaceuticals, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company, International Medication Systems, Limited. Package NDCs: 0409-4902-34, 0409-6648-02, 0409-7517-16, 76329-3302-1.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | 76329-3302-1 | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1) | Available | 2026-09-16 |
| Hospira, Inc., a Pfizer Company | 0409-6648-02 | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02) | Limited Availability | 2026-08-24 |
| Hospira, Inc., a Pfizer Company | 0409-7517-16 | Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-4902-34 | Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34) | Not stated | 2025-11-07 |
Source facts
Grouped generic ingredient: Dextrose Monohydrate 50% Injection · 4 package records
Therapeutic categories: Endocrinology/Metabolism, Gastroenterology, Pediatric
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.